- Home
- RDIB vs SLDB Comparison
RDIB vs SLDB Comparison
Compare RDIB & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- SLDB
- Stock Information
- Founded
- RDIB 1937
- SLDB 2013
- Country
- RDIB United States
- SLDB United States
- Employees
- RDIB N/A
- SLDB N/A
- Industry
- RDIB Movies/Entertainment
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDIB Consumer Discretionary
- SLDB Health Care
- Exchange
- RDIB Nasdaq
- SLDB Nasdaq
- Market Cap
- RDIB 140.2M
- SLDB 124.7M
- IPO Year
- RDIB N/A
- SLDB 2018
- Fundamental
- Price
- RDIB $6.37
- SLDB $3.19
- Analyst Decision
- RDIB
- SLDB Strong Buy
- Analyst Count
- RDIB 0
- SLDB 12
- Target Price
- RDIB N/A
- SLDB $17.75
- AVG Volume (30 Days)
- RDIB 3.4K
- SLDB 630.7K
- Earning Date
- RDIB 03-28-2025
- SLDB 03-12-2025
- Dividend Yield
- RDIB N/A
- SLDB N/A
- EPS Growth
- RDIB N/A
- SLDB N/A
- EPS
- RDIB N/A
- SLDB N/A
- Revenue
- RDIB $197,270,000.00
- SLDB N/A
- Revenue This Year
- RDIB N/A
- SLDB N/A
- Revenue Next Year
- RDIB $14.40
- SLDB N/A
- P/E Ratio
- RDIB N/A
- SLDB N/A
- Revenue Growth
- RDIB N/A
- SLDB N/A
- 52 Week Low
- RDIB $5.78
- SLDB $2.92
- 52 Week High
- RDIB $21.34
- SLDB $15.05
- Technical
- Relative Strength Index (RSI)
- RDIB 44.73
- SLDB 35.60
- Support Level
- RDIB $6.05
- SLDB $2.92
- Resistance Level
- RDIB $6.77
- SLDB $3.48
- Average True Range (ATR)
- RDIB 0.15
- SLDB 0.24
- MACD
- RDIB -0.01
- SLDB 0.05
- Stochastic Oscillator
- RDIB 73.10
- SLDB 41.44
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.